Clinical trials: Fibrosing Interstitial Lung Disease
Lung Diseases, Interstitial
Study of Progression to Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Incidence/Management and Treatment
The primary objective for this trial is to investigate the incidence probability of progression to Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) in patients with fibrosing ILD other than Idiopathic Pulmonary Fibrosis…
- Trial name
- NCT05875532
- Where
- United States
- Volunteers
- 34,960 people
- Sponsor
- Boehringer Ingelheim
Lung Diseases, Interstitial
Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
The aim of the current study is to investigate the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) defined as patients who present with features of diffuse…
- Trial name
- INBUILD® (NCT02999178)
- Testing
- Nintedanib
- Where
- 153 sites in United States, Argentina and 13 more
- Volunteers
- 663 people
- Sponsor
- Boehringer Ingelheim
Lung Diseases, Interstitial
A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)
The main objective of the study is to evaluate dose-exposure and safety of nintedanib in children and adolescents with fibrosing Interstitial Lung Disease (ILD).
- Trial name
- InPedILD® (NCT04093024)
- Testing
- Nintedanib
- Where
- 43 sites in United States, Argentina and 19 more
- Volunteers
- 39 people
- Sponsor
- Boehringer Ingelheim
Lung Diseases, Interstitial
INREAL - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation
The primary objective of this observational study is to investigate the correlation between changes from baseline at 52 weeks in forced vital capacity (FVC) and changes from baseline at 52 weeks in dyspnea score points or cough…
- Trial name
- INREAL (NCT04702893)
- Testing
- Nintedanib
- Where
- 21 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Boehringer Ingelheim
Lung Diseases, Interstitial
A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)
This study is open to children and adolescents with interstitial lung disease (ILD) that causes lung fibrosis. This is a study for people who took part in a previous study called InPedILD (study 1199-0337) and for people who are…
- Trial name
- NCT05285982
- Testing
- Nintedanib (Ofev®)
- Where
- 28 sites in United States, Argentina and 15 more
- Volunteers
- 54 people
- Sponsor
- Boehringer Ingelheim
Lung Diseases, Interstitial
Post-marketing Surveillance of Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype in Japan
The primary objective is to evaluate the incidence of adverse drug reactions (focus on hepatic function disorders) of Ofev Capsules under the real world setting in patients with Chronic fibrosing Interstitial Lung Diseases with a…
- Trial name
- NCT04559581
- Testing
- Nintedanib
- Where
- Japan
- Volunteers
- 425 people
- Sponsor
- Boehringer Ingelheim
Interstitial Lung Disease, Diffuse Parenchymal Lung Disease
Hydroxychloroquine (HCQ) in Pediatric Interstitial Lung Disease (ILD)
This is an exploratory Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multinational study investigating the initiation or withdrawal of hydroxychloroquine in subjects with chILD.
- Conditions
- Interstitial Lung Disease, Diffuse Parenchymal Lung Disease, Children´s Interstitial Lung Disease
- Trial name
- HCQ-chILD-EU (NCT02615938)
- Testing
- Hydroxychloroquine sulfate
- Where
- 9 sites in Germany
- Volunteers
- 35 people
- Sponsor
- Matthias Griese
Alveolitis, Fibrosing, Fibrosis, Pulmonary
Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis
Medicines that decrease blood pressure in the lungs may help idiopathic pulmonary fibrosis (IPF) patients function better. This study will test whether sildenafil improves the ability to exercise in patients with pulmonary…
- Conditions
- Alveolitis, Fibrosing, Fibrosis, Pulmonary, Hypertension, Pulmonary
- Trial name
- NCT00359736
- Testing
- sildenafil
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- VA Office of Research and Development
Lung Diseases, Interstitial
A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
This study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic Pulmonary Fibrosis (IPF) can join the study.
- Trial name
- NCT05321082
- Testing
- BI 1015550
- Where
- 400 sites in United States, Argentina and 43 more
- Volunteers
- 1,178 people
- Sponsor
- Boehringer Ingelheim
Lung Diseases, Interstitial
A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
The main objective is to assess long term tolerability and safety of treatment with oral nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) who have complete (and did not prematurely discontinue…
- Trial name
- NCT03820726
- Testing
- Nintedanib
- Where
- 121 sites in United States, Argentina and 13 more
- Volunteers
- 435 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Fibrosis
A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of…
- Trial name
- NCT04308681
- Testing
- BMS-986278
- Where
- 119 sites in United States, Argentina and 16 more
- Volunteers
- 403 people
- Sponsor
- Bristol-Myers Squibb
Lung Diseases, Interstitial
A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease
The purpose of this study is to evaluate the efficacy and safety of pirfenidone in participants with fibrosing interstitial lung disease (ILD) who cannot be classified with moderate or high confidence into any other category of…
- Trial name
- NCT03099187
- Testing
- Pirfenidone
- Where
- 66 sites in Australia, Belgium and 12 more
- Volunteers
- 253 people
- Sponsor
- Hoffmann-La Roche
Lung Diseases, Interstitial
A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis
This study in China is open to people with progressive lung fibrosis (chronic fibrosing ILDs with progressive phenotype) who are at least 18 years old.
- Trial name
- NCT05065190
- Testing
- Nintedanib
- Where
- 16 sites in China
- Volunteers
- 81 people
- Sponsor
- Boehringer Ingelheim